TCP
IMMU

Tourbillon Capital Partners’s Immunomedics Inc IMMU Stock Holding History

Tourbillon Capital Partners’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,500,000
Closed -$5.5M – 86
2016
Q4 		$5.5M Hold
1,500,000
– – 0.11% 60
2016
Q3 		$4.88M Hold
1,500,000
– – 0.1% 67
2016
Q2 		$3.48M Buy
+1,500,000
New +$5.01M 0.07% 58

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Tourbillon Capital Partners's IMMU Position: Q1 2017 in Review

Tourbillon Capital Partners sold out of Immunomedics Inc (IMMU) in Q1 2017, closing a stake of 2,400,000 shares — an estimated $8.81M sold.

Tourbillon Capital Partners first reported a position in IMMU in Q2 2016 and held it in 3 quarters. The position peaked at $8.81M in Q4 2016. 124 funds tracked by Wall St. Rank hold IMMU as of Q1 2017.

  • Tourbillon Capital Partners reported no remaining Immunomedics Inc position as of Q1 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 2,400,000 Immunomedics Inc shares in Q1 2017, an estimated $8.81M.
  • Tourbillon Capital Partners first reported a position in Immunomedics Inc in Q2 2016 and held it in 3 quarters.
  • Tourbillon Capital Partners's Immunomedics Inc position peaked at $8.81M in Q4 2016.
  • 124 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2017.

Based on Tourbillon Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.